NCT01771146

Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer

A Prospective Evaluation of Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancreas Cancer (Baylor University Medical Center and Texas Oncology Experience)

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Baylor Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A prospective evaluation of neoadjuvant FOLFIRINOX regimen in patients with non-metastatic pancreas cancer (Baylor University Medical Center and Texas Oncology Experience)

Detailed description

Patients with pancreas cancer will be enrolled and treated with a planned course of 6 cycles (3 months) of chemotherapy with FOLFIRINOX prior to undergoing surgical resection.

Conditions

• Pancreas Cancer
• Localized Pancreas Cancer
• Non-metastatic Pancreas Cancer

Interventions

Type	Name	Description
DRUG	FOLFIRINOX Regimen	6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin® (Oxaliplatin) 85 mg per square meter 2-hour IV infusion Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion

Timeline

• Start date: 2012-10-01
• Primary completion: 2017-09-01
• Completion: 2020-09-01
• First posted: 2013-01-18
• Last updated: 2017-01-31

Locations

1 site across 1 country: United States